Tambon Nai Mueang

Researchers are studying the effectiveness of a tetravalent dengue vaccine TDV in reducing hospital stays due to dengue in children and adolescents aged 6 to 12 years living in Southeast Asian countries with high dengue transmission, including Thailand, Indonesia, and Malaysia. This observational study focuses on participants in a community-based cohort who may or may not receive the vaccine as part of a pilot public vaccination program where TDV is already approved. The study particularly aims to assess the vaccines effectiveness against less common dengue virus types DENV-3 and DENV-4. The study includes a nested case-control design with two groups cases who are hospitalized children or adolescents with confirmed dengue infection, and matched controls who live in the same neighborhood but have not been hospitalized with dengue. Participants are followed individually for up to 3 years within the cohort. The study is non-interventional, observing outcomes based on vaccination status within the existing vaccination program. Participants will be monitored through active hospital surveillance to identify dengue hospitalizations confirmed by laboratory testing. Data collected includes blood samples for RT-PCR testing, clinical diagnosis, and hospitalization records. Researchers will measure the rate of hospitalization due to dengue virus infections by serotype and baseline dengue immune status. The primary outcome is dengue-related hospitalization up to 36 months. Parents or legal representatives provide consent and assent for participants, including agreement for blood sample collection and follow-up over the study period.

Researchers are evaluating the efficacy, immune response, and safety of the CHIKV VLP vaccine to prevent Chikungunya disease in adolescents and adults aged 12 years and older. This phase 3b study uses advanced infectious disease models and analytics to select regions and clinical sites, set study timelines, and optimize study parameters against local Chikungunya virus conditions to address challenges in assessing vaccine efficacy. Participants will be randomly assigned to receive either the CHIKV VLP vaccine with an adjuvant or a placebo. The vaccine consists of a 0.8 mL intramuscular injection containing 40 g of CHIKV VLP adsorbed on aluminum hydroxide. The study includes two groups one receiving the active vaccine and one receiving placebo. It follows participants from 14 days after vaccination up to 1095 days to assess disease prevention and immune response. During the study, participants will be monitored for confirmed acute, chronic, and severe Chikungunya disease cases. Safety is tracked by recording local and unsolicited adverse events up to 28 days postvaccination and serious or medically attended events throughout the study. Blood samples will measure antibody responses at three weeks postvaccination. The total study duration is up to three years, allowing detailed follow-up on vaccine effects and safety.

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Peptic ulcer bleeding is a leading cause of upper gastrointestinal bleeding worldwide. Researchers are evaluating a high-dose, locally made oral proton pump inhibitor omeprazole compared to the standard intravenous proton pump inhibitor pantoprazole to prevent rebleeding after successful endoscopic treatment. This trial aims to confirm if the oral treatment is not worse than the standard IV treatment in reducing rebleeding and to monitor gastric acid levels over 24 hours. Participants will receive either oral omeprazole at 40 mg twice daily or continuous intravenous pantoprazole at 8 mg per hour, both for 72 hours after endoscopic hemostasis. These two treatment groups are compared in a randomized design to assess their effects on preventing peptic ulcer rebleeding. During the study, patients will be monitored for rebleeding events within 3 and 30 days. Gastric pH will be measured over 24 hours to evaluate acid suppression. The main outcome is the rate of rebleeding within 3 days. The trial includes safety monitoring and follow-up for up to 30 days. Participants clinical status and treatment responses will be carefully recorded throughout the study period.